- Home
- WD vs DAWN Comparison
WD vs DAWN Comparison
Compare WD & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WD | DAWN |
|---|---|---|
| Founded | 1937 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WD | DAWN |
|---|---|---|
| Price | $50.95 | $21.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $78.33 | $24.43 |
| AVG Volume (30 Days) | 239.8K | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.64 | N/A |
| Revenue | ★ $1,234,306,000.00 | $158,182,000.00 |
| Revenue This Year | $20.60 | $55.03 |
| Revenue Next Year | $7.79 | $28.12 |
| P/E Ratio | $30.60 | ★ N/A |
| Revenue Growth | 8.99 | ★ 20.60 |
| 52 Week Low | $42.12 | $5.64 |
| 52 Week High | $90.00 | $21.50 |
Technical Indicators
Market Signals| Indicator | WD | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 63.66 | 79.82 |
| Support Level | $42.34 | $10.30 |
| Resistance Level | $66.25 | $21.50 |
| Average True Range (ATR) | 1.44 | 0.03 |
| MACD | 1.06 | -0.31 |
| Stochastic Oscillator | 94.34 | 77.78 |
Price Performance
Historical ComparisonAbout WD Walker & Dunlop Inc
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.